Sökning: id:"swepub:oai:lup.lub.lu.se:56025de3-4213-472a-b911-a637a71a1e06" >
Baseline Prostate-s...
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
-
- Preston, Mark A. (författare)
- Brigham and Women's Hospital / Harvard Medical School
-
- Gerke, Travis (författare)
- H. Lee Moffitt Cancer Center & Research Institute,Harvard University
-
- Carlsson, Sigrid V. (författare)
- Sahlgrenska Academy,Memorial Sloan-Kettering Cancer Center
-
visa fler...
-
- Signorello, Lisa (författare)
- Harvard University,National Cancer Institute, USA
-
- Sjoberg, Daniel D. (författare)
- Memorial Sloan-Kettering Cancer Center
-
- Markt, Sarah C. (författare)
- Harvard University
-
- Kibel, Adam S. (författare)
- Brigham and Women's Hospital / Harvard Medical School
-
- Trinh, Quoc Dien (författare)
- Brigham and Women's Hospital / Harvard Medical School
-
- Steinwandel, Mark (författare)
- Vanderbilt University
-
- Blot, William (författare)
- Vanderbilt University
-
- Vickers, Andrew J. (författare)
- Memorial Sloan-Kettering Cancer Center
-
- Lilja, Hans (författare)
- Lund University,Lunds universitet,Institutionen för translationell medicin,Medicinska fakulteten,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Department of Translational Medicine,Faculty of Medicine,Clinical Chemistry, Malmö,Lund University Research Groups
-
- Mucci, Lorelei A. (författare)
- Harvard University
-
- Wilson, Kathryn M. (författare)
- Brigham and Women's Hospital / Harvard Medical School,Harvard University
-
visa färre...
-
Brigham and Women's Hospital / Harvard Medical School H Lee Moffitt Cancer Center & Research Institute (creator_code:org_t)
- Elsevier BV, 2019
- 2019
- Engelska.
-
Ingår i: European Urology. - : Elsevier BV. - 0302-2838. ; 75:3, s. 399-407
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://europepmc.or...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Prostate-specific antigen (PSA) measurement in midlife predicts long-term prostate cancer (PCa) mortality among white men. Objective: To determine whether baseline PSA level during midlife predicts risk of aggressive PCa in black men. Design, setting, and participants: Nested case-control study among black men in the Southern Community Cohort Study recruited between 2002 and 2009. A prospective cohort in the southeastern USA with recruitment from community health centers. A total of 197 incident PCa patients aged 40–64 yr at study entry and 569 controls matched on age, date of blood draw, and site of enrollment. Total PSA was measured in blood collected and stored at enrollment. Outcome measurements and statistical analysis: Total and aggressive PCa (91 aggressive: Gleason ≥7, American Joint Committee on Cancer stage III/IV, or PCa-specific death). Exact conditional logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs) for PCa by category of baseline PSA. Results and limitations: Median PSA among controls was 0.72, 0.80, 0.94, and 1.03 ng/ml for age groups 40–49, 50–54, 55–59, and 60–64 yr, respectively; 90th percentile levels were 1.68, 1.85, 2.73, and 3.33 ng/ml. Furthermore, 95% of total and 97% of aggressive cases had baseline PSA above the age-specific median. Median follow-up was 9 yr. The OR for total PCa comparing PSA >90th percentile versus ≤median was 83.6 (95% CI, 21.2–539) for 40–54 yr and 71.7 (95% CI, 23.3–288) for 55–64 yr. For aggressive cancer, ORs were 174 (95% CI, 32.3–infinity) for 40–54 yr and 51.8 (95% CI, 11.0–519) for 55–64 yr. A composite endpoint of aggressive PCa based on stage, grade, and mortality was used and is a limitation. Conclusions: PSA levels in midlife strongly predicted total and aggressive PCa among black men. PSA levels among controls were similar to those among white controls in prior studies. Patient summary: Prostate-specific antigen (PSA) level during midlife strongly predicted future development of aggressive prostate cancer among black men. Targeted screening based on a midlife PSA might identify men at high risk while minimizing screening in those men at low risk. Prostate-specific antigen (PSA) level during midlife strongly predicted total and aggressive prostate cancer among black men. Risk-stratified screening based on midlife PSA might retain the benefits of screening while reducing harms.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- African-American
- Baseline
- Prostate cancer
- Prostate-specific antigen
- Screening
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Preston, Mark A.
-
Gerke, Travis
-
Carlsson, Sigrid ...
-
Signorello, Lisa
-
Sjoberg, Daniel ...
-
Markt, Sarah C.
-
visa fler...
-
Kibel, Adam S.
-
Trinh, Quoc Dien
-
Steinwandel, Mar ...
-
Blot, William
-
Vickers, Andrew ...
-
Lilja, Hans
-
Mucci, Lorelei A ...
-
Wilson, Kathryn ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
European Urology
- Av lärosätet
-
Lunds universitet